Boehringer Ingelheim

For Healthcare Professionals

Logout

Boehringer Ingelheim

Therapeutic Area
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Section Overview

Therapeutic Area

Section Overview

Metabolic

Oncology

Respiratory

Inflammation
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See all products

Products

See all products
Resources
Contact
Logout

Boehringer Ingelheim

Leave this field blank

Empagliflozin

Empagliflozin
Iinagliptin

Format

Sort by

Reset all filters

PDF

EK22||EMPA-KIDNEY's Further Results on Annual Rate of Change in eGFR

Download Opens in new tab

1:47

Empagliflozin Cardio Renal Metabolic Benefits

Watch Now Opens in new tab

PDF

2022 ADA Standard of Care

Download Opens in new tab

2:03

Prof Wu: "Empagliflozin cuts Insulin Need in Patients with T2D"

Watch Now Opens in new tab

1:40

Prof Verma: "ESC guidelines 2019- Managing T2D with CV Risk, Changing Perspective with SGLT2i"

Watch Now Opens in new tab

2:19

Prof Ted Wu: "T2D Patients with A1c Well-controlled and High CV Risk, Would you Add Empagliflozin and Why?"

Watch Now Opens in new tab

Pagination

Load More

Home
Metabolic
Empagliflozin

Sitemap

Therapeutic Area

Resources

BI logo

Privacy
Terms of use
Sitemap
Contact

This website is intended for healthcare professionals in Singapore. The contents of this website are for information purposes only and are not intended to substitute for advice, treatment or recommendations of a healthcare professional. For your health concerns and other questions about symptoms, treatment or medication, consult a healthcare professional.